CHUGAI PHARMACEUTICAL CO., LTD.

Chugai Pharmaceutical launches new TV commercial featuring Tori Matsuzaka, titled 'Innovation Lab / Cancer Genomic Medicine,' showcasing personalized cancer treatment through unique technology and science.

TARA-002 shows 72% six-month complete response rate in high-risk NMIBC patients, with 100% CR in BCG-Unresponsive and 64% in BCG-Naïve patients. Favorable safety profile with no Grade 2+ treatment-related adverse events. Protara to host conference call today at 8:30 a.m. ET.

Galderma's Phase III OLYMPIA 1 trial of nemolizumab for moderate-to-severe prurigo nodularis achieved primary and secondary goals, showing significant itch reduction and lesion clearance compared to placebo. The therapy, recently approved by the FDA, aims to provide rapid relief from PN's primary symptom, itch.

The OLYMPIA 1 trial showed nemolizumab significantly improved itch and skin lesions in prurigo nodularis patients, with rapid responses as early as Week 4.

Chugai Pharmaceutical Co., Ltd. does not guarantee the accuracy, completeness, or usefulness of information on its website and will not be responsible for any damages resulting from its use. For more details, refer to the 'Terms and Conditions of Website Use.'

Roche reports SKYSCRAPER-01 phase III study did not meet primary endpoint of overall survival for tiragolumab plus Tecentriq vs. Tecentriq alone in PD-L1-high NSCLC. Safety profile consistent, no new signals. Data to be presented in 2025.

Zenyaku Kogyo and Chugai Pharmaceutical received MHLW approval for Rituxan (rituximab) for chronic idiopathic thrombocytopenic purpura (ITP) in children, expanding its use beyond adults. This follows a request by the Japanese Society of Paediatric Haematology/Oncology and a public knowledge-based application process. Rituxan, an anti-CD20 monoclonal antibody, targets B cells implicated in ITP pathogenesis, offering a treatment option for pediatric ITP patients resistant to primary therapies.

Halozyme proposes to acquire Evotec for €11.00 per share, creating a leading global pharma services company with capabilities in drug discovery, biologic manufacturing, and drug delivery technologies, diversifying and scaling Halozyme's revenue and EBITDA into the next decade. The all-cash transaction would be funded by cash on hand and new debt, with expected net leverage less than 2x two years post-close.

ALK1510 and ALK0413 cells, derived from ALK fusion gene–positive NSCLC patients, were established for genetic and cell-biological analyses. Various drugs and reagents were used in in vitro and in vivo assays to study cell proliferation, phosphoproteomic analysis, and other cellular processes. Statistical analysis was conducted using JMP Ver. 15.0.0.

The global spinal muscular atrophy market is projected to grow from USD 2,013.5 million in 2024 to USD 4,823.9 million by 2031, at a CAGR of 13.3%. Key drivers include FDA approvals for drugs like Zolgensma and Evrysdi, rising awareness, and increasing gene therapies. North America is expected to dominate due to its established healthcare infrastructure.